Valuation: Alkermes plc

Market Cap 836.3Cr 721.98Cr 677.33Cr 616.92Cr 1.16TCr 80TCr 1.18TCr 7.94TCr 3.11TCr 40TCr 3.14TCr 3.07TCr 1,33300Cr P/E 2026 *
-97.7x
P/E 2027 * 68.6x
Enterprise Value 910.69Cr 786.2Cr 737.58Cr 671.8Cr 1.26TCr 87TCr 1.28TCr 8.65TCr 3.39TCr 44TCr 3.42TCr 3.35TCr 1,45100Cr EV / Sales 2026 *
4.99x
EV / Sales 2027 * 4.64x
Free-Float
89.44%
Yield 2026 *
-
Yield 2027 * -
1 day+1.61%
1 week+0.91%
Current month+1.76%
1 month-5.44%
3 months+33.00%
6 months+51.52%
Current year+78.16%
1 week 48.5
Extreme 48.5
51.66
1 month 47.66
Extreme 47.66
53.88
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
05/08/26 Free

Chief Executive Officer

2,17,534 0.1297%
03/08/26 Sell

Compliance Officer

-2,034 0.0012%
03/08/26 Fiscal year

Chief Technology Officer

19,000 0.0113%
Change 5-day change 1-year change 3-year change Capi.($)
+1.61%+0.91%+71.60%+73.57% 836.3Cr
-0.11%-2.28%+2.16%+19.70% 4.88TCr
+4.07%+2.43%+483.70%+623.80% 4.54TCr
+4.33%+0.98%+12.80%+88.53% 4.12TCr
+1.94%-0.31%+26.24%+12.62% 3.97TCr
-0.50%0.00%+20.60%+60.49% 3.26TCr
-0.44%-3.22% - - 1.62TCr
+3.22%-0.88%+30.42%+135.47% 1.67TCr
-0.09%-0.09%+3.71%+29.48% 1.41TCr
+2.35%+3.48%+82.95%+43.41% 1.37TCr
Average +1.61%+0.11%+81.58%+120.78% 2.77TCr
Weighted average by Cap. +1.81%+0.05%+102.15%+150.85%

Financials

2026 *2027 *
Net sales 182.49Cr 157.54Cr 147.8Cr 134.62Cr 253.13Cr 17TCr 256.64Cr 1.73TCr 678.96Cr 8.74TCr 685.14Cr 670.31Cr 29TCr 194.48Cr 167.9Cr 157.52Cr 143.47Cr 269.76Cr 19TCr 273.5Cr 1.85TCr 723.58Cr 9.32TCr 730.17Cr 714.36Cr 31TCr
Net income -8.99Cr -7.76Cr -7.28Cr -6.63Cr -12Cr -859.75Cr -13Cr -85Cr -33Cr -430.73Cr -34Cr -33Cr -1.43TCr 12Cr 10Cr 9.74Cr 8.87Cr 17Cr 1.15TCr 17Cr 114.2Cr 45Cr 576.2Cr 45Cr 44Cr 1.92TCr
Net Debt 74Cr 64Cr 60Cr 55Cr 103.19Cr 7.11TCr 104.62Cr 706.3Cr 276.77Cr 3.56TCr 279.3Cr 273.25Cr 12TCr 67Cr 58Cr 54Cr 49Cr 93Cr 6.41TCr 94Cr 636.05Cr 249.25Cr 3.21TCr 251.52Cr 246.07Cr 11TCr
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
17/26/17 $49.85 +1.61% 7,64,040
14/26/14 $49.06 -0.79% 12,67,828
13/26/13 $49.45 -1.65% 15,46,632
12/26/12 $50.28 +2.17% 13,15,646
11/26/11 $49.21 -0.38% 13,73,601
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
49.85USD
Average target price
56.00USD
Spread / Average Target
+12.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock